CD274 and neoplasm: This is accomplished by mechanisms that suppress anti-tumor immunity, such as increased expression of molecules like PD-L1 that block T-cell action or decreased production of human leucocyte antigen (HLA) class I molecules that hinder antigen presentation (150–153).